期刊
NANOMEDICINE
卷 15, 期 2, 页码 145-161出版社
FUTURE MEDICINE LTD
DOI: 10.2217/nnm-2018-0455
关键词
asialoglycoprotein receptor; chitosan; drug delivery; glycyrrhetinic acid; hepatocellular carcinoma
资金
- National Natural Science Foundation of China [81372668, 81502527, 81874231, 81874208]
- Natural Science Foundation of Hubei Province of China [2015CFB527]
- Fundamental Research Funds for the Central Universities, China [2014QN064]
- Research Grant of Union Hospital, Tongji Medical College, HUST [02.03.2015-74]
Aim: The dual-ligand glycyrrhetinic acid and galactose-modified chitosan nanoparticles were designed to further improve the targeting capability to hepatocellular carcinoma (HCC). Materials & methods: The dual-ligand glycyrrhetinic acid and galactose-modified chitosan nanoparticles were fabricated by using ionic gelation method and their characteristics have been measured. Furthermore, the biodistribution and biocompatibility of this targeting vehicle were investigated in vitro and in vivo, respectively. Results: The targeting vehicle was specifically internalized into hepatoma cells in vitro and accumulated into tumor tissue in vivo with high efficacy. Moreover, the vehicle did not induce inflammation reaction and affect morphologies and organ functions. Conclusion: The targeting accumulation in HCC tissue and great biocompatibility of the dual-ligand modified chitosan nanoparticles highlight the potential of delivering anticancer agents into HCC cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据